TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37202130

Group type: EXPERIMENTAL
Intervention: Suggested deadline (1 week)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Suggested deadline (2 weeks)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Suggested deadline (4 weeks)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Planning tool
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Planning tool plus suggested deadline (1 week)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Planning tool plus suggested deadline (2 weeks)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Planning tool plus suggested deadline (4 weeks)
Number of subjects: 40000

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40000
Study: 37202143

Group type: EXPERIMENTAL
Intervention: Neurocognitive function evaluation over time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-perceived quality of life and fatigue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P300 in an electroencephalography (EEG) oddball paradigm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Power spectrum in resting state EEG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum and cerebrospinal fluid levels of biomarkers of neuronal damage, neuroplasticity, proinflammatory and anti-inflammatory markers
Number of subjects: 0
Study: 37202147

Group type: EXPERIMENTAL
Intervention: Orally aerosolized adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV)
Number of subjects: 0
Study: 37202152

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty plus aggressive medical management (AMM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aggressive medical management (AMM) alone
Number of subjects: 0
Study: 37202253

Group type: EXPERIMENTAL
Intervention: Education on umbilical cord care
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 2
Study: 37202261

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 260
Study: 37202447

Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37202497

Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and/or strength training)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 27
Study: 37202530

Group type: EXPERIMENTAL
Intervention: Omega 3 supplement (40 mg/kg/day) for 2 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 70
Study: 37202647

Group type: EXPERIMENTAL
Intervention: Right-hand opening-closing motor task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Right shoulder abduction-adduction motor task
Number of subjects: 20
Study: 37202781

Group type: EXPERIMENTAL
Intervention: Intraoral scanning using the Emerald (Planmeca) intraoral scanner
Number of subjects: 113
Study: 37202813

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg p.o./day for 2 weeks escalated to 10 mg p.o./day for 6 weeks)
Number of subjects: 15
Study: 37202822

Group type: EXPERIMENTAL
Intervention: TAPER (team approach to polypharmacy evaluation and reduction)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 39
Study: 37202831

Group type: EXPERIMENTAL
Intervention: CRC evidence-based interventions implemented at health centers
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched control health centers (C)
Number of subjects: 12
Study: 37202893

Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no bacterial lysates)
Number of subjects: 24
Study: 37203207

Group type: EXPERIMENTAL
Intervention: Postoperative 3D endoanal ultrasound (EAUS) at 3 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination of gas in fistula and clinical finding of fluid discharge through the external fistula opening at 3 months
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Postoperative 3D EAUS at late control (6-12 months)
Number of subjects: 95
Study: 37203237

Group type: EXPERIMENTAL
Intervention: Fit2Thrive intervention (core intervention with Fitbit + Fit2Thrive smartphone app)
Number of subjects: 269
Study: 37203243

Group type: EXPERIMENTAL
Intervention: TiNO-coated stents
Number of subjects: 1491

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1491
Study: 37203300

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 257
Study: 37203336

Group type: EXPERIMENTAL
Intervention: Insulin resistance
Number of subjects: 26

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intranasal insulin
Number of subjects: 26
Study: 37203351

Group type: EXPERIMENTAL
Intervention: Painful electrical stimulation using four electrodes positioned on the left side according to the three branches of the trigeminal nerve and the greater occipital nerve, randomized stimulation site, repeated 10 times per session, across three sessions (30 trials per site).
Number of subjects: 87
Study: 37203392

Group type: EXPERIMENTAL
Intervention: Exosomal microRNA‑4516
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Exosomal microRNA‑203
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Secretory frizzled‑related protein 1 (SFRP1)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Correlation with SYNTAX score
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Correlation with cardiac troponin I (cTnI) and low-density lipoprotein (LDL)
Number of subjects: 93
Study: 37203441

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587
Study: 37203558

Group type: EXPERIMENTAL
Intervention: Robotic repair
Number of subjects: 101

Group type: COMPARATOR
Intervention: Laparoscopic repair
Number of subjects: 101
Study: 37204076

Group type: EXPERIMENTAL
Intervention: Qigong (n=11)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise/Nutrition (n=13)
Number of subjects: 24
Study: 37204106

Group type: EXPERIMENTAL
Intervention: INO-3107 administered by intramuscular injection followed by electroporation on weeks 0, 3, 6, and 9.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: INO-3107
Number of subjects: 21
Study: 37204144

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham TTNS
Number of subjects: 240
Study: 37204277

Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate/Dexmethylphenidate, treated for up to 12 months
Number of subjects: 0
Study: 37204336

Group type: EXPERIMENTAL
Intervention: Motivational interview to patients
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Motivational interview to patients and caregivers
Number of subjects: 510

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 510
Study: 37204358

Group type: EXPERIMENTAL
Intervention: Same-Day Discharge (SDD) protocol
Number of subjects: 2332

Group type: EXPERIMENTAL
Intervention: Same-Day Discharge (SDD) group
Number of subjects: 2332

Group type: COMPARATOR
Intervention: Non-Same-Day Discharge (non-SDD) group
Number of subjects: 2332
Study: 37204382

Group type: EXPERIMENTAL
Intervention: Machine learning-based clustering of echocardiographic variables
Number of subjects: 429

Group type: COMPARATOR
Intervention: Conventional analysis
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Decision tree based on severity of MR, LV systolic strain <21%, and indexed LA volume >42 mL/m
Number of subjects: 429
Study: 37204397

Group type: EXPERIMENTAL
Intervention: Quantitative Flow Ratio assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard assessment methods
Number of subjects: 0
Study: 37204411

Group type: EXPERIMENTAL
Intervention: Phone call strategy
Number of subjects: 345

Group type: COMPARATOR
Intervention: Mail letter strategy
Number of subjects: 345
Study: 37204435

Group type: EXPERIMENTAL
Intervention: Knowledge-driven model
Number of subjects: 3419

Group type: EXPERIMENTAL
Intervention: Data-driven model
Number of subjects: 3419

Group type: EXPERIMENTAL
Intervention: Decision tree model
Number of subjects: 3419

Group type: EXPERIMENTAL
Intervention: A-DOUBLE-SSI risk score
Number of subjects: 3419

Group type: EXPERIMENTAL
Intervention: Bootstrap internal validation of knowledge-driven model
Number of subjects: 3419
Study: 37204443

Group type: EXPERIMENTAL
Intervention: Carotid-jugular angle (CJA) measurement
Number of subjects: 105
Study: 37204608

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 379
Study: 37204631

Group type: EXPERIMENTAL
Intervention: AVT02 alternating with the reference product (Humira)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Reference product only (Humira)
Number of subjects: 550
Study: 37204754

Group type: EXPERIMENTAL
Intervention: Demographic items (female participants)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Demographic items (participants with spouses/partners as informants)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Health items (better cognitive function of the participant)
Number of subjects: 330
Study: 37204788

Group type: EXPERIMENTAL
Intervention: Intensive treatment (<120 mm Hg)
Number of subjects: 7918

Group type: COMPARATOR
Intervention: Standard treatment (<140 mm Hg)
Number of subjects: 7918
Study: 37204794

Group type: EXPERIMENTAL
Intervention: 1200 IU vitamin D3 supplementation
Number of subjects: 546

Group type: COMPARATOR
Intervention: 400 IU vitamin D3 supplementation
Number of subjects: 546

Group type: COMPARATOR
Intervention: 400 IU vitamin D3 supplementation with maternal 25(OH)D < 30 ng/mL
Number of subjects: 546

Group type: COMPARATOR
Intervention: 400 IU vitamin D3 supplementation with maternal 25(OH)D ≥ 30 ng/mL
Number of subjects: 546
Study: 37204830

Group type: EXPERIMENTAL
Intervention: iStride gait device
Number of subjects: 5
Study: 37204831

Group type: EXPERIMENTAL
Intervention: Work Ability Index (WAI) assessment
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Negative predictors of work ability
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Positive predictors of work ability
Number of subjects: 494
Study: 37204838

Group type: EXPERIMENTAL
Intervention: CareConekta app with supportive phone calls, WhatsApp messages, or both when traveling >50 km from the study area for >7 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control arm receiving the app with no additional support
Number of subjects: 200
Study: 37204853

Group type: EXPERIMENTAL
Intervention: Xiaomi Mi Band 5
Number of subjects: 45
Study: 37204858

Group type: EXPERIMENTAL
Intervention: VR calm room
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physical calm room
Number of subjects: 60
Study: 37204866

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Confluent atrophy, disrupted retrofoveal ellipsoid zone, and choroidal neovascularization
Number of subjects: 39
Study: 37204935

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 37205012

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 3116

Group type: EXPERIMENTAL
Intervention: Autologous reconstruction
Number of subjects: 3116

Group type: EXPERIMENTAL
Intervention: Direct-to-implant (DTI)
Number of subjects: 3116

Group type: EXPERIMENTAL
Intervention: Tissue expander/immediate (TE/I)
Number of subjects: 3116
Study: 37205399

Group type: EXPERIMENTAL
Intervention: Successful vesicovaginal fistula repair
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Qualitative inquiry among key stakeholders
Number of subjects: 40
Study: 37205420

Group type: EXPERIMENTAL
Intervention: SRP-001
Number of subjects: 0

Group type: COMPARATOR
Intervention: ApAP
Number of subjects: 0
Study: 37205428

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation and Biopsychosocial Self-Management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical Care
Number of subjects: 0
Study: 37205489

Group type: EXPERIMENTAL
Intervention: Deliberative engagement process including an introductory session, workbook, facilitated small group deliberative forum, and post-forum survey.
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Deliberative engagement process
Number of subjects: 680
Study: 37205558

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 37205559

Group type: EXPERIMENTAL
Intervention: Uplifts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hassles
Number of subjects: 0
Study: 37205569

Group type: EXPERIMENTAL
Intervention: Social media intervention to increase lung cancer screening awareness, knowledge, and uptake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard awareness methods)
Number of subjects: 0
Study: 37205592

Group type: EXPERIMENTAL
Intervention: Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters (Moderna mRNA-1273, Pfizer-BioNTech BNT162b2, Sanofi CoV2 preS DTM-AS03)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prototype/Wildtype Vaccines
Number of subjects: 0
Study: 37205666

Group type: EXPERIMENTAL
Intervention: ICG-guided sentinel node (SN) mapping
Number of subjects: 0
Study: 37205721

Group type: EXPERIMENTAL
Intervention: IDA1 (ivermectin 150 μg/kg + albendazole 400 mg + diethylcarbamazine 6 mg/kg)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: IDA3 (three consecutive daily doses of IDA)
Number of subjects: 574

Group type: COMPARATOR
Intervention: IA (ivermectin 150 μg/kg + albendazole 400 mg)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: IDA treatments (both IDA1 and IDA3 combined)
Number of subjects: 574
Study: 37205804

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 163
Study: 37206279

Group type: EXPERIMENTAL
Intervention: GS-0189 as monotherapy and in combination with rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GS-0189
Number of subjects: 0
Study: 37206996

Group type: EXPERIMENTAL
Intervention: CT-STAR (cone-beam computed tomography-guided stereotactic adaptive radiation therapy)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CT-STAR
Number of subjects: 7

Group type: COMPARATOR
Intervention: nonadaptive SBRT
Number of subjects: 7
Study: 37207143

Group type: EXPERIMENTAL
Intervention: Vanucizumab in combination with mFOLFOX-6 chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab (VEGF-A inhibitor) in combination with mFOLFOX-6 chemotherapy
Number of subjects: 0
Study: 37207300

Group type: EXPERIMENTAL
Intervention: Switched endocrine therapy (fulvestrant or exemestane) plus ribociclib
Number of subjects: 119

Group type: COMPARATOR
Intervention: Switched endocrine therapy (fulvestrant or exemestane) plus placebo
Number of subjects: 119
Study: 37207306

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ado-trastuzumab emtansine
Number of subjects: 0
Study: 37207382

Group type: EXPERIMENTAL
Intervention: Eteplirsen (30 mg/kg, once-weekly intravenously for 10 weeks, continuing at 30 mg/kg up to 96 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Eteplirsen (30 mg/kg)
Number of subjects: 15
Study: 37207654

Group type: EXPERIMENTAL
Intervention: tislelizumab-chemotherapy
Number of subjects: 263

Group type: COMPARATOR
Intervention: placebo-chemotherapy
Number of subjects: 263
Study: 37207655

Group type: EXPERIMENTAL
Intervention: PI3K inhibitors (specifically alpelisib)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Tumor organoids
Number of subjects: 148

Group type: COMPARATOR
Intervention: Site-of-origin samples
Number of subjects: 148
Study: 37207788

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 37207810

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure for 6 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Waitlist control (usual care for pain management)
Number of subjects: 300
Study: 37207924

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS) with improved technique
Number of subjects: 2604

Group type: COMPARATOR
Intervention: Cobalt chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 2604

Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 2604

Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 2604
Study: 37207923

Group type: EXPERIMENTAL
Intervention: Tricuspid transcatheter edge-to-edge repair with the TriClip system (Abbott)
Number of subjects: 0
Study: 37208019

Group type: EXPERIMENTAL
Intervention: Personalized multi-modal pre-habilitation algorithm and ERAS pathway
Number of subjects: 414

Group type: COMPARATOR
Intervention: Historic control group
Number of subjects: 414

Group type: COMPARATOR
Intervention: Prospective control group
Number of subjects: 414

Group type: COMPARATOR
Intervention: Health insurance controls
Number of subjects: 414
Study: 37208126

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study: 37208131

Group type: EXPERIMENTAL
Intervention: BNP measured preoperatively
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: BNP categories based on conversion from NT-pro-BNP categories
Number of subjects: 431

Group type: COMPARATOR
Intervention: NT-pro-BNP values predicted by an existing formula
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Troponin measurements on postoperative days 1, 2, and 3
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Composite outcome of MINS and vascular death
Number of subjects: 431
Study: 37208132

Group type: EXPERIMENTAL
Intervention: Projection-based augmented reality exposure treatment system (P-ARET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo exposure treatment (IVET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group (WL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P-ARET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVET
Number of subjects: 0

Group type: COMPARATOR
Intervention: WL
Number of subjects: 0
Study: 37208133

Group type: EXPERIMENTAL
Intervention: MK-7 (333 µg/day)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 37208135

Group type: EXPERIMENTAL
Intervention: Transperineal prostate biopsy
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Transrectal prostate biopsy
Number of subjects: 1700
Study: 37208138

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) assessment
Number of subjects: 139
Study: 37208142

Group type: EXPERIMENTAL
Intervention: Projection-based AR exposure therapy with multiple stimuli (P-ARET MS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Projection-based AR exposure therapy with a single stimulus (P-ARET SS)
Number of subjects: 80
Study: 37208143

Group type: EXPERIMENTAL
Intervention: Qualitative data collection through interviews or focus groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative data collection of self-reported demographic characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of orientation tools and educational materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthesis of values and perspectives of patients and family members
Number of subjects: 0
Study: 37208187

Group type: EXPERIMENTAL
Intervention: Oropharyngeal swab (OPS)
Number of subjects: 23102

Group type: COMPARATOR
Intervention: Nasopharyngeal swab (NPS)
Number of subjects: 23102

Group type: COMPARATOR
Intervention: Saliva specimen
Number of subjects: 23102
Study: 37208282

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Number of subjects: 2916

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 2916
Study: 37208431

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose 7.5 mg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose 15 mg/kg
Number of subjects: 35
Study: 37208512

Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 36
Study: 37208556

Group type: EXPERIMENTAL
Intervention: Ponatinib + hyper-CVAD
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ponatinib + steroids
Number of subjects: 2

Group type: COMPARATOR
Intervention: Imatinib + hyper-CVAD
Number of subjects: 2

Group type: COMPARATOR
Intervention: Imatinib monotherapy induction + imatinib-containing consolidation
Number of subjects: 2
Study: 37208654

Group type: COMPARATOR
Intervention: Initial measurements (no intervention)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Follow-up after 8 years
Number of subjects: 52
Study: 37208674

Group type: EXPERIMENTAL
Intervention: Customized corneal crosslinking (cCXL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard corneal crosslinking (sCXL)
Number of subjects: 0
Study: 37208675

Group type: EXPERIMENTAL
Intervention: 20 mL of 2% lidocaine with epinephrine 1:200,000
Number of subjects: 66

Group type: COMPARATOR
Intervention: 10 mL 2% lidocaine with epinephrine 1:200,000 plus 2 mL sodium bicarbonate 4.2% (total of 12 mL)
Number of subjects: 66
Study: 37208687

Group type: EXPERIMENTAL
Intervention: Trust in PrEP provider
Number of subjects: 451
Study: 37208787

Group type: EXPERIMENTAL
Intervention: Helmet NIV
Number of subjects: 80

Group type: COMPARATOR
Intervention: High-flow nasal oxygen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intubated patients
Number of subjects: 80
Study: 37208998

Group type: EXPERIMENTAL
Intervention: Dapagliflozin, 10 mg, once daily
Number of subjects: 5795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5795
Study: 37209152

Group type: EXPERIMENTAL
Intervention: 50 IU/kg unfractionated heparin (UFH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100 IU/kg unfractionated heparin (UFH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg enoxaparin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1 mg/kg enoxaparin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 25
Study: 37209201

Group type: EXPERIMENTAL
Intervention: Brochure and empathic communication (intervention group)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 250
Study: 37209238

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interferon/ribavirin (prior treatment)
Number of subjects: 60